

1 **Clinical manifestations and disease severity of SARS-CoV-2 infection among**  
2 **infants in Canada**

3  
4 **Pierre-Philippe Piché-Renaud MD<sup>1\*</sup>, Luc Panetta MD<sup>2,3\*</sup>, Daniel S. Farrar MPH<sup>4</sup>,**  
5 **Charlotte Moore-Hepburn MD<sup>5,6,7</sup>, Olivier Drouin MDCM MSc MPH<sup>8,9</sup>, Jesse Papenburg**  
6 **MD MSc<sup>10,11,12</sup>, Marina I. Salvadori MD<sup>10,13</sup>, Melanie Laffin<sup>14</sup>, Fatima Kakkar<sup>#</sup> MD MPH<sup>3</sup>,**  
7 **Shaun K. Morris<sup>#</sup> MD MPH<sup>1,4,7,15</sup> for the Canadian Paediatric Surveillance Program**  
8 **COVID-19 Study Team**

9  
10 **\*Co-first authors**

11 **#Co-senior authors**

12  
13 <sup>1</sup>Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada

14 <sup>2</sup>Paediatric Emergency Department, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Lyon, France

15 <sup>3</sup>Division of Infectious Diseases, CHU Sainte-Justine, Montreal, Canada

16 <sup>4</sup>Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada

17 <sup>5</sup>Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Canada

18 <sup>6</sup>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

19 <sup>7</sup>Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

20 <sup>8</sup>Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada

21 <sup>9</sup>Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal,  
22 Canada

23 <sup>10</sup>Division of Pediatric Infectious Diseases, Department of Pediatrics, The Montreal Children's Hospital,  
24 McGill University Health Centre, Montreal, Quebec, Canada

25 <sup>11</sup>Division of Medical Microbiology, Department of Clinical Laboratory Medicine, McGill University Health  
26 Centre, Montreal, Quebec, Canada

27 <sup>12</sup>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec,  
28 Canada

29 <sup>13</sup>Public Health Agency of Canada, Ottawa

30 <sup>14</sup>Canadian Paediatric Surveillance Program

31 <sup>15</sup>Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

32

33

34 **Corresponding authors:**

35 Shaun K. Morris, Division of Infectious Diseases, The Hospital for Sick Children, 555

36 University Ave, Toronto, ON, M5G 1X8, Canada. Email: [shaun.morris@sickkids.ca](mailto:shaun.morris@sickkids.ca) Phone:

37 416-813-6625; Fax: 416-813-8404

38

39 Fatima Kakkar, Division of Infectious Diseases, Centre Hospitalier Universitaire Sainte-Justine,

40 3175 Chemin Cote Sainte-Catherine, Montreal, QC, H3T 1C5, Canada. Email:

41 [fatima.kakkar@umontreal.ca](mailto:fatima.kakkar@umontreal.ca). Phone: 514-345-4931 x6885

42

43 **Funding Source:** OD & FK are supported by a Clinical Research Scholars Award, from the

44 Fonds de recherche du Québec – Santé. We gratefully acknowledge the financial support

45 received from the Public Health Agency of Canada to the Canadian Paediatric Surveillance

46 Program, in support of the COVID-19 study.

47

48 **Words (Body): 3342**

49 **Words (Abstract): 339**

50 **Key Points**

51 **Question:** What are the spectrum of illness, disease severity, and characteristics associated with  
52 hospitalization in infants with SARS-CoV-2 infection?

53 **Findings:** A total of 531 cases were reported to the Canadian Paediatric Surveillance Program,  
54 including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. In total, 20 infants  
55 met criteria for severe disease (3.8%). Infants' characteristics associated with admission included  
56 age of less than one month and comorbid conditions.

57 **Meaning:** This study provides data on the spectrum of disease, severity, and characteristics  
58 associated with admission due to COVID-19 in infants, which informs clinical management and  
59 public health interventions in this specific population.

60 **Abstract**

61 **Importance:** There are limited data on outcomes of SARS-CoV-2 infection among infants (<1  
62 year of age). In the absence of approved vaccines for infants, understanding characteristics  
63 associated with hospitalization and severe disease from COVID-19 in this age group will help  
64 inform clinical management and public health interventions.

65 **Objective:** The objective of this study was to describe the clinical manifestations, disease  
66 severity, and characteristics associated with hospitalization among infants infected with the  
67 initial strains of SARS-CoV-2.

68 **Design:** Prospective study of infants with SARS-CoV-2 from April 8<sup>th</sup> 2020 to May 31<sup>st</sup> 2021.

69 **Setting:** National study using the infrastructure of the Canadian Paediatric Surveillance Program,  
70 reporting inpatients and outpatients seen in clinics and emergency departments.

71 **Participants:** Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection.

72 **Exposure:** Infant-level characteristics associated with hospitalization for COVID-19.

73 **Main outcomes and Measures:** Cases were classified as either: 1) Non-hospitalized patient with  
74 SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related  
75 hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as  
76 asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable  
77 logistic regression was performed to identify characteristics associated with hospitalization.

78 **Results:** A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199  
79 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were  
80 admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other  
81 than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common  
82 presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral

83 intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of  
84 hospitalization compared to infants with no comorbid conditions (aOR=4.53, 2.06-9.97), and  
85 infants <1 month had higher odds of hospitalization than infants aged 1-3 months (aOR=3.78,  
86 1.97-7.26). In total, 20 infants (3.8%) met criteria for severe disease.

87 **Conclusions and Relevance:** We describe one of the largest cohorts of infants with SARS-CoV-  
88 2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having  
89 mild disease. Comorbid conditions and younger age were associated with COVID-19-related  
90 hospitalization amongst infants.

91 **BACKGROUND**

92 Approximately two years into the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
93 2) pandemic, the clinical presentation of Coronavirus Disease 2019 (COVID-19) and risk factors  
94 for disease severity among adults and older children have now been well documented.<sup>1-5</sup>

95 However, there is still an important knowledge gap regarding disease manifestation and risk  
96 factors for severe disease in newborns and infants infected with SARS-CoV-2.

97 To date, there have been few published studies describing outcomes in infants with SARS-CoV-  
98 2 infection, with conflicting data on young age as a risk factor for severe disease.<sup>6-8</sup> Some studies  
99 have reported that infants are more at risk of severe disease than older children, while others  
100 have shown similar risk across pediatric age groups. More specifically, some authors have  
101 suggested that neonates (<28 days of life)<sup>9,10</sup> and infants (<1 year-old) may be at higher risk of  
102 severe disease than older children.<sup>1,11-15</sup> However, most of these studies have not included data  
103 on non-hospitalized and asymptomatic infants with SARS-CoV-2 infection and as such, the  
104 complete disease spectrum in this age group remains unknown.

105 A thorough understanding of COVID-19 in infants, including characteristics that are associated  
106 with hospitalization, would inform management and preventive interventions for this specific age  
107 group, including future vaccination strategies.<sup>16,17</sup> The objective of this study was to describe the  
108 clinical manifestations and disease severity among infants with microbiologically confirmed  
109 SARS-CoV-2 infection reported to the Canadian Paediatric Surveillance Program (CPSP)  
110 between April 2020 and May 2021, and to explore infant characteristics that may be associated  
111 with hospitalization for COVID-19.

112

113

## 114 **METHODS**

### 115 **Study design and setting**

116 The CPSP is a national public health surveillance platform designed to collect information on  
117 rare childhood disorders, and is administered jointly by the Canadian Paediatric Society and the  
118 Public Health Agency of Canada (PHAC).<sup>18</sup> Using weekly active surveillance for incident cases  
119 and online case reporting forms, the CPSP COVID-19 study gathered information through its  
120 network of more than 2,800 paediatricians and paediatric subspecialists across Canada.<sup>18,19</sup>  
121 Beginning on April 8, 2020, CPSP participants were asked to report on three different groups:  
122 (1) children admitted to hospital with acute SARS-CoV-2 infection, (2) non-hospitalized children  
123 with acute COVID-19 AND at least one chronic comorbid condition or less than one year of age  
124 and (3) children with multisystem inflammatory syndrome in children (MIS-C) associated with  
125 COVID-19.<sup>20</sup> The detailed study protocol including case definitions and case report form for all  
126 COVID-19-related CPSP studies are available at: <https://www.cpsp.cps.ca/surveillance/etude/covid-19>.  
127

128 This particular study was designed to analyze patient-level data on infants less than one year of  
129 age who were infected with SARS-CoV-2. Data on demographic characteristics, epidemiology  
130 of cases, clinical and laboratory features, treatments, and outcomes were collected. Clinical  
131 syndromes were reported directly from clinicians (e.g., pneumonia, bronchiolitis). A clinical  
132 syndrome of upper respiratory tract infection (URTI) was constructed post hoc when symptoms  
133 of coryza or rhinorrhea were reported. Cases of multisystem inflammatory syndrome in children  
134 (MIS-C) were not included in this study. To optimize case capture, this study also included  
135 additional active case finding from three large pediatric centers: The Hospital for Sick Children  
136 (HSC, Toronto, Ontario), CHU Sainte-Justine (HSJ, Montréal, Québec) and the Montreal

137 Children's Hospital (MCH, Montréal, Québec). For these three centers, weekly extraction of  
138 infection prevention and control lists were performed using the hospital Electronic Medical  
139 Records (EMR) systems, which includes all children who had a positive SARS-CoV-2 PCR from  
140 the hospital laboratory, and all children who tested positive in another center and subsequently  
141 transferred for hospital admission. Of note, these three centers are located in the two most  
142 populous provinces that had the most COVID-19 cases in Canada during the study time frame  
143 (Québec and Ontario).<sup>21</sup>

144

### 145 **Study definitions**

146 Cases were classified into one of the following mutually exclusive categories: 1) Non-  
147 hospitalized infants who tested positive for SARS-CoV-2; 2) COVID-19-related hospitalization:  
148 an infant hospitalized due to clinical features directly related to the SARS-CoV-2 infection; 3)  
149 Non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2, isolation, or  
150 social reasons). For each hospitalized infant, at least two study team members (PPPR, LP, SKM,  
151 or FK) reviewed all available clinical and diagnostic information on the case report form to  
152 ensure the accuracy of the physician-reported case classification. Any discrepancies in the  
153 assignment of category of illness were resolved by reporting physician follow-up and/or  
154 consensus discussion by the study team.

155 A COVID-19 disease severity classification was adapted to the CPSP case reporting form from  
156 the World Health Organization COVID-19 Clinical Characterisation and Management Working  
157 Group scale<sup>22</sup>, and was defined as such: 1) Asymptomatic: Patients reported to have no clinical  
158 signs or symptoms of COVID-19; 2) Outpatient care: any reported symptoms of COVID-19 and  
159 no admission required (including from pediatric COVID-19 clinics and pediatric emergency



160 department); 3) Mild disease (inpatient): Admitted with symptoms of COVID-19, but no targeted  
161 treatment against COVID-19 required and no respiratory support required; 4) Moderate disease:  
162 Admitted with symptoms of COVID-19 and received low-flow oxygen, had oxygen therapy  
163 above home baseline needs or received targeted treatment against COVID-19 including  
164 remdesivir or steroids; 5) Severe disease: Infants who experienced acute respiratory distress  
165 syndrome (ARDS) or severe neurological symptoms (seizures or coma), or who required  
166 intensive care unit (ICU) admission, ventilation (including high-flow nasal cannula, non-invasive  
167 ventilation, conventional mechanical ventilation, high-frequency oscillatory ventilation) or  
168 vasopressors. The detailed criteria for severity classification can be found in the supplementary  
169 material (eTable 1). Cases were included from the first wave (occurred between March and June  
170 2020), the second wave (September 2020 to January 2021) and the third wave (between March  
171 and May 2021) of the pandemic in Canada. With the emergence of SARS-CoV-2 variants of  
172 concerns (VOC) in Canada starting on December 26, 2020, the study was amended to gather data  
173 on SARS-CoV-2 mutation testing (N501Y and E484K) for detection of the Alpha (B.1.1.7), Beta  
174 (B.1.351) and Gamma (P.1) lineages from the three hospitals that have performed active case  
175 finding (HSC, HSJ and MCH), including on previously reported cases. Cases occurring before  
176 December 26, 2020 were assumed to be 'not a confirmed VOC'.

177 Infant age was categorized as neonates (<1 month; 1-28 days old), 1–3-month-old infants (29-91  
178 days old), 4–6-month-old infants (92-182 days old) and 7–12-month-old infants (183-365 days  
179 old). These age categories were based on the significant differences in the routine management  
180 of well-appearing febrile infants aged <1 months and older infants.<sup>23</sup> Amongst patients aged  
181 older than 3 months, a category was created for infants aged more than 6 months of age since  
182 this population has been included in clinical trials on COVID-19 vaccination and thus have

183 specific considerations. Prematurity was defined as gestational of less than 37 weeks, and  
184 preterm infants were included based on their chronologic age.

185

## 186 **Statistical Analysis**

187 Demographic characteristics were analyzed using frequencies, percentages, medians, and  
188 interquartile ranges. Differences in age groups and severity categories were assessed using  
189 Fisher's exact tests,  $\chi^2$  tests, and Kruskal-Wallis tests. A statistical significance threshold of  
190  $\alpha=0.05$  was used for all comparisons. Multivariable logistic regression was performed to identify  
191 infant characteristics associated with hospitalization due to COVID-19, after excluding infants  
192 hospitalized with incidental SARS-CoV-2 infection. Variables for the primary adjusted model  
193 were selected a priori on the basis of literature review and available elements on the case report  
194 form. Given a smaller available sample size for the post hoc VOC model, the variable with the  
195 lowest pairwise correlation with hospitalization (i.e., infant sex) was excluded while VOC status  
196 was forced into the adjusted model. Odds ratios (OR) and 95% confidence intervals (CI) were  
197 calculated. Unadjusted comparisons between infants hospitalized because of COVID-19 with  
198 severe and non-severe disease were performed using a Wilcoxon rank-sum test and chi-square  
199 test (excluding cases that were admitted for reasons other than COVID-19). Logistic regression  
200 to identify factors associated with disease severity could not be performed due to the small  
201 number of infants with severe disease. Sensitivity analyses were conducted using only the cases  
202 from the three centres that systematically screened for inclusion all infants who tested positive  
203 for SARS-CoV-2 (HSC, HSJ and MCH). Analyses were conducted using Stata 17 (StataCorp,  
204 College Station, TX). Due to CPSP privacy policies, frequencies between one and four were  
205 masked and reported as '<5'. In some instances, the results of subgroup analyses were presented  
206 as ranges to prevent back-calculation of frequencies <5.

207

## 208 **Ethical approval**

209 The CPSP operates under the legal authority derived from Section 4 of the Department of Health  
210 Act and Section 3 of the Public Health Agency of Canada Act. Ethics approval was obtained  
211 from the Public Health Agency of Canada and Health Canada Research Ethics Board (REB  
212 2020-002P), The Hospital for Sick Children (REB 1000070001) and the Institutional Review  
213 Board of the Centre Hospitalier Universitaire Sainte-Justine (IRB MP-21-2021-2901) as well as  
214 at individual sites, as required by local policies. In Québec, the study was conducted as a  
215 multicenter study, with clinical data collected by the study co-investigators.

216

## 217 **RESULTS**

### 218 **Patient demographics**

219 From April 8<sup>th</sup>, 2020 to May 31<sup>st</sup>, 2021 a total of 531 infants aged <1 year old were reported to  
220 CPSP, including 199 (37.5%) hospitalized and 332 (62.5%) non-hospitalized infants (Figure 1).  
221 Cases were reported from all provinces with the majority from Québec and Ontario (Figure 2).  
222 Full data capture was not possible for Alberta because of delays in securing the appropriate data-  
223 transfer agreements. Eighty-one infants (15.4%) were neonates ( $\leq 28$  days old), of whom 13 were  
224  $\leq 7$  days old and 67 between 8 to 28 days old (one infant could not be categorized). Most infants  
225 had a known close contact with a confirmed case of SARS-CoV-2 infection (n=302, 58.5%),  
226 with either their parents (n=247; 79.2%), siblings (n=46, 14.7%), other relatives (n=51, 16.4%),  
227 or non-family members (n=13, 4.2%). Other infant characteristics are shown in Table 1.

228

229

## 230 **Clinical characteristics**

231 From all reported infants, 66 (12.4%) were asymptomatic from SARS-CoV-2 infection (Table 2).  
232 Among symptomatic infants, the most common presenting symptoms were fever (n=353,  
233 66.5%), coryza (n=250, 47.1%), cough (n=198, 37.3%) and decreased oral intake (n=133,  
234 25.0%) (Table 2). The most common clinical syndromes were URTI (n=321, 60.5%), followed  
235 by gastrointestinal syndrome (161, 30.3%). Few infants had bronchiolitis (n=20, 3.8%) or  
236 pneumonia (n=14, 2.6%). A total of 59 infants (11.1%) had at least one comorbidity, including  
237 congenital heart disease (n=20, 3.8%), neurologic/neurodevelopmental disease (n=19, 3.6%) and  
238 chronic lung disease (n=10, 1.9%). Fourteen infants (2.6%) had more than one co-morbidity.  
239 Most infants were born at term (n=445, 88.8%), with 29 (5.8%) born prematurely between 34  
240 and 36 weeks of gestation and 27 infants (5.4%) born before 34 weeks of gestation (Table 1).

241

## 242 **Hospitalization for COVID-19**

243 Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-  
244 related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19 (Table 1).  
245 Neonates (<1 month) were more likely to be hospitalized for COVID-19, with an adjusted odds  
246 ratio (aOR) of 3.78 (95% CI, 1.97 – 7.26) when compared with infants aged 1-3 months. Infants  
247 aged 4-6 months and 7-12 months were less likely to be admitted than infants aged 1-3 months  
248 with an aOR of 0.24 (95% CI, 0.12 – 0.47) and aOR of 0.13 (95% CI, 0.06 – 0.25), respectively  
249 (Table 3). The median age for infants managed as outpatients was 160 days (Interquartile range  
250 [IQR], 73 – 263 days), and the median age for infants admitted for COVID-19-related illness  
251 was 37 days (IQR, 22 – 115 days, p<0.001). Odds ratios for COVID-19 admission by continuous  
252 infant age, with infants at 100 days of age as the reference point are reported in the

253 Supplementary eFigure 1. Infants born before 34 weeks of gestation were at increased odds of  
254 being hospitalized for COVID-19 compared to infants born at term (aOR, 3.54; 95% CI, 1.19 –  
255 10.46). Infants with  $\geq 1$  comorbid condition(s) were also at increased odds of hospitalization for  
256 COVID-19 compared to infants with no known comorbid conditions (aOR, 4.53; 95% CI, 2.06 –  
257 9.97). Sensitivity analyses were conducted to confirm results among the two Montreal and the  
258 Toronto centres with systematic case reporting. While associations between hospitalization,  
259 comorbidities, and young age remained consistent, these analyses showed a higher proportion of  
260 non-hospitalized infants (n=275/374, 73.5%) and the association between preterm birth before 34  
261 weeks of gestation and hospital admission was not statistically significant (aOR 2.21; 95% CI,  
262 0.55–8.95, Supplementary eTable 2 and eTable 3). In these analyses, similarly to the analyses  
263 performed on the full dataset, comorbidities and young age were also associated with admission  
264 for COVID-19 (Table 4 and Table 5).

265

### 266 **Severe COVID-19 disease amongst infants hospitalized for COVID-19**

267 Amongst infants hospitalized because of COVID-19-related illness, 111 of 141 infants (78.7%)  
268 had mild disease, 10 (7.1%) had moderate disease and 20 (14.2%) had severe disease. A  
269 comparison of disease severity classification of our cases using the objective CPSP criteria,  
270 versus the Dong severity criteria is shown in Supplementary eTable 7. Fewer than five infants  
271 with COVID-19 died. Fourteen infants (9.9%) were admitted to the ICU, with <5 infants  
272 requiring non-invasive ventilation and 5 infants requiring mechanical ventilation (Table 2). A  
273 higher proportion of neonates aged <1 month (26.5%) admitted for COVID-19 required  
274 respiratory support (oxygen, non-invasive ventilation and mechanical ventilation) compared to  
275 infants aged 1-12 months (11.0%, p=0.02) (Supplementary eTable 5). The median age of

276 inpatients with severe disease was 19 days (IQR 10–83) compared to 42 days (IQR 23–94)  
277 among inpatients with non-severe disease ( $p=0.03$ ). Inpatients with severe disease were more  
278 likely to be premature ( $<37$  weeks' gestation; 7/20 [35.0%]) than inpatients with non-severe  
279 disease (11/119 with known prematurity status [9.2%];  $p=0.005$ ).

280

## 281 **Treatment and management**

282 Almost all infants managed as outpatients (314 of 332, 94.6%) did not receive any treatment,  
283 whereas 61 (43.3%) infants hospitalized for COVID-19 did not receive any treatment ( $p<0.001$ )  
284 (Supplementary eTable 6). Antibiotics were the most frequent treatment modality (94/473,  
285 19.9%), and neonates aged  $<1$  month received antibiotics more frequently (35/69, 47.7%) than  
286 infants aged 1-3 months (34/138, 24.6%) and infants aged 4-12 months (25/262, 9.5%,  $p<0.001$ ).  
287 Few infants received systemic corticosteroids (11/473, 2.3%), including seven infants who  
288 received steroids for a non-COVID-19 related reason (for example, laryngitis). Less than five  
289 infants ( $<1.1\%$ ) received remdesivir, and no patients were treated with biologic response  
290 modifying drugs, anticoagulation (e.g. prophylactic, therapeutic, mechanical), or chloroquines  
291 (e.g. chloroquine, hydroxychloroquine).

292

## 293 **SARS-CoV-2 variants of concern**

294 From centers contributing SARS-CoV-2 lineage data (HSC, HSJ and MCH), 60 infants screened  
295 positive for VOC, all of whom tested positive on or after February 24, 2021. This included 39  
296 infants with the Alpha VOC and 21 infants with another VOC (including Beta, Gamma or  
297 unspecified N501Y+ VOC) (Supplementary eTable 3). In our VOC adjusted model, no SARS-  
298 CoV-2 lineage was associated with an increased odds of hospitalization in infants (Table 3). The

299 aOR of hospitalization for VOC compared to the SARS-CoV-2 ancestor strain was 0.63 (95% CI,  
300 0.27 – 1.48). The phase of the pandemic (first, second or third wave) was not associated with an  
301 increased odds of hospitalization in infants.

302

## 303 **DISCUSSION**

304 This study describes the clinical manifestations and severity of disease in infants less than one  
305 year of age with microbiologically-confirmed SARS-CoV-2 infection in Canada in outpatient  
306 and hospital settings prior to May 2021. While previous studies on COVID-19 in infants have  
307 focused only on hospitalized patients with symptomatic disease and may therefore have  
308 overestimated the severity of COVID-19 in this age group, this study provides a more complete  
309 description of the possible range of presentations of infants with SARS-CoV-2 infection by  
310 including a subset of infants seen in outpatient settings.<sup>9,24,25</sup>

311 Similar to the results of previous studies, including meta-analyses and systematic reviews on  
312 pediatric COVID-19, we report that severe COVID-19 is uncommon in infants, especially when  
313 compared to adults and adolescents.<sup>26-29</sup> It is thought that the difference in severity from SARS-  
314 CoV-2 infection between age groups relates to distinct immune responses and expression in  
315 receptors of angiotensin-converting enzyme-2 (ACE-2) in younger children.<sup>30</sup> However,  
316 consistent with previous studies, we found that amongst infants, neonates aged <1 month were at  
317 increased risk for hospitalization.<sup>9,10,13,15,31</sup> Although a low threshold for admission in infants  
318 aged less than 6 to 12 weeks who present with fever may impact hospitalization rates, a larger  
319 proportion of neonates aged <1 month admitted for COVID-19 have also required respiratory  
320 support compared to older infants, including 5 who required mechanical ventilation.<sup>23</sup> The  
321 increased severity of SARS-CoV-2 infection seen in young neonates may relate to their small

322 airways and reduced innate immune responses, especially in the absence of passive immunity  
323 from maternal antibodies against SARS-CoV-2.<sup>32,33</sup> Several studies and reports have  
324 demonstrated successful placental transmission of SARS-CoV-2 antibodies after maternal  
325 vaccination.<sup>34-36</sup> Thus, in the absence of any COVID-19 vaccine approved for use in young  
326 infants, an important strategy to protect neonates against severe SARS-CoV-2 may be through  
327 maternal immunization. With multiple jurisdictions reporting lower COVID-19 vaccine coverage  
328 in pregnant women compared to the general population, efforts should be made to optimize their  
329 acceptance and uptake of COVID-19 vaccines.<sup>37,38</sup>

330 Our results also suggest that preterm infants (<37 weeks of gestation) may be at higher risk of  
331 severe COVID-19 compared to term infants. While a multivariable analysis revealed higher odds  
332 of admission in preterm infants, this result was not consistent in our sensitivity analysis on the  
333 data from centres with systematic case reporting. To date, there have been very few data  
334 describing the spectrum of COVID-19 manifestations in infants who are born prematurely. Some  
335 case reports have described severe disease requiring intubation in premature neonates infected  
336 with SARS-CoV-2, whereas others have described an overall mild course.<sup>39-43</sup> Thus, further  
337 research on the spectrum of illness of SARS-CoV-2 infection in this population is needed.

338 The emergence of new SARS-CoV-2 lineages have raised concerns for differences in  
339 susceptibility and virulence in the pediatric population.<sup>44</sup> In Ontario and Québec, the provinces  
340 from which most of our study subjects have been reported, the third wave of the pandemic that  
341 occurred from March to May 2021 was mostly comprised of the Alpha variant.<sup>45</sup> Reassuringly,  
342 we did not find any significant difference in the proportion of infants admitted for COVID-19  
343 during the third wave of the pandemic, or between SARS-CoV-2 lineages. However, we have  
344 limited data on Delta (B.1.617) variant, and no data on Omicron (B.1.1.529) variant. The first



345 cases of the Delta VOC were identified in Québec on April 21, 2021 by using whole genome  
346 sequencing (WGS), as the variant is negative for the detection of N501Y and E484K mutations  
347 (widely used for VOC screening).<sup>16</sup> Since we were unable to obtain data on WGS in our study,  
348 SARS-CoV-2 isolates that were negative for both N501Y and E484K mutations from April 21<sup>st</sup>  
349 to May 31<sup>st</sup> may have been Delta VOC that were misclassified as wild-type SARS-CoV-2. All  
350 data preceded the Omicron wave of the pandemic. Further data on possible increased  
351 susceptibility and severe outcomes in infants secondary to the Delta and Omicron VOC will be  
352 needed.

353 This study is also limited by the voluntary nature of reporting in the CPSP system, and therefore,  
354 we have not captured data on every infant who tested positive for SARS-CoV-2 in Canada, nor  
355 infants who were infected but for whom parents did not seek health care. Under-reporting of  
356 outpatient cases may have also caused an information bias in comparison between hospitalized  
357 and non-hospitalized patients, likely leading to over-estimation of the proportion of infants who  
358 require hospitalization for COVID-19. For cases diagnosed in the first days of life, we were also  
359 unable to differentiate SARS-CoV-2 infection acquired congenitally versus postnatally, and the  
360 possible impact of the method of transmission on disease severity in infants. Although we  
361 described the distribution of cases by population group, we are unable to draw any conclusions  
362 because this variable was reported by physicians, and not by families. Lastly, we were unable to  
363 obtain information on the vaccination status or prior infection of the infants' mothers.

364

## 365 **CONCLUSION**

366 Our study has shown that SARS-CoV-2 infection prior to the Omicron wave generally causes  
367 mild illness in infants, but that comorbid conditions and younger age were associated with

368 COVID-19-related hospitalization. Thorough understanding of the spectrum of disease and  
369 characteristics associated with severe disease in young infants may inform the clinical  
370 management and public health interventions targeted to this population. In the absence of  
371 available COVID-19 vaccines in infants, increasing acceptance and uptake of COVID-19  
372 vaccines in pregnant women is likely to be an important strategy to protect young infants against  
373 SARS-CoV-2 infection.

374

375

### 376 **ACKNOWLEDGEMENTS**

377 The authors wish to thank the paediatricians, paediatric sub-specialists, and health professionals  
378 who voluntarily respond to CPSP surveys. We also wish to thank Dr. Jim Kellner, MD, MSc for  
379 his guidance and support, as well as the members and leadership of the Paediatric Inpatient  
380 Research Network (PIRN) for cases reported. We thank Lorraine Piché for her assistance at the  
381 Montreal Children's Hospital site. Lastly, the authors also wish to thank members of the CPSP  
382 Scientific Steering Committee who oversee the program and the managers and staff of the CPSP  
383 who implement the program.

384

385

386 **COMPLETE LIST OF CPSP AUTHORS**

Olivier Drouin	Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montréal, Que. Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal, Que.
Charlotte Moore-Hepburn	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont.
Daniel S. Farrar	Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ont.
Krista Baerg	Department of Pediatrics, University of Saskatchewan, Saskatoon, Sask. Jim Pattison Children’s Hospital, Saskatchewan Health Authority, Saskatoon, Sask.
Kevin Chan	Department of Children’s and Women’s Health, Trillium Health Partners, Mississauga, Ont. Department of Pediatrics, University of Toronto, Toronto, Ont.
Claude Cyr	Service de Soins Intensifs Pédiatriques, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que. Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Que.
Elizabeth J. Donner	Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Ont.
Joanne E. Embree	Department of Paediatrics and Child Health, University of Manitoba, Winnipeg, Man. Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Man.
Catherine Farrell	Division of Pediatric Intensive Care, Department of Pediatrics, CHU Sainte-Justine, Montréal, Que.
Sarah Forgie	Division of Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, Alta. Stollery Children's Hospital, Edmonton, Alta.
Ryan Giroux	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont.
Kristopher T. Kang	Department of Pediatrics, University of British Columbia, Vancouver, BC.
Melanie King	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa
Melanie Laffin	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa
Julia Orkin	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ont.

Jesse Papenburg	Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital, Montréal, Que. Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montréal, Que.
Catherine M. Pound	Division of General Pediatrics, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ont.
Victoria E. Price	Division of Pediatric Hematology/Oncology, Department of Pediatrics, Dalhousie University, Halifax, NS.
Rupena Purewal	Department of Pediatrics, University of Saskatchewan, Saskatoon, Sask. Division of Pediatric Infectious Diseases, Jim Pattison Children's Hospital, Saskatchewan Health Authority, Saskatoon, Sask.
Manish Sadarangani	Department of Pediatrics, University of British Columbia, Vancouver, BC. Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC.
Marina I. Salvadori	Public Health Agency of Canada, Ottawa Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital, Montréal, Que.
Karina A. Top	Department of Pediatrics, Dalhousie University, Halifax, NS.
Isabelle Viel-Thériault	Division of Infectious Diseases, Department of Pediatrics, CHU de Québec-Université Laval, Québec City, Que.
Fatima Kakkar	Division of Infectious Diseases, CHU Sainte-Justine, Montréal, Que.
Shaun K. Morris	Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ont. Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ont. Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.


387

388

389

390 **Conflict of interest statement:** JP reports grants to his institution from MedImmune, Merck,  
391 Sanofi Pasteur and AbbVie, and speaker fees from AbbVie and AstraZeneca, all outside of the  
392 submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation,  
393 the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for  
394 Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck,  
395 Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his  
396 institute, and he has not received any personal payments. PPPR has been co-investigator on an  
397 investigator-led project funded by Pfizer that is unrelated to this study. RP is a consultant for  
398 Verity Pharmaceuticals. SKM is co-principal investigator on an investigator-led grant from  
399 Pfizer, has served on an ad-hoc advisory boards for Pfizer and Sanofi Pasteur, and has received  
400 speaker fees from GlaxoSmithKline, all unrelated to this study.

401 **Figure 1: Flow chart of cases reported to the CPSP COVID-19 study until May 31, 2021.**




402

403


404

405 **Figure 2a. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by**  
406 **Canadian region\***



407  
408 \*Western/Northern Canada includes Alberta, British Columbia, Manitoba, Northwest Territories, Nunavut,  
409 Saskatchewan, and Yukon. Atlantic Canada includes Newfoundland & Labrador, New Brunswick, Nova Scotia, and  
410 Prince Edward Island.

411  
412 **Figure 2b. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by**  
413 **admission status**



415 **Table 1. Characteristics of infants with SARS-CoV-2 infection in Canada.**

Characteristics	All Infants	Outpatients	Inpatients		P value
			Not COVID-19 related	COVID-19 related	
<b>Total cases reported, N</b>	531	332	58	141	---
<b>Infant age (days), median (IQR)<sup>1</sup></b>	112 (43–240)	158 (75–263)	138 (35–263)	37 (20–87)	<0.001
<b>Infant age category, n (%)<sup>1</sup></b>					<0.001
<1 month	81 (15.4)	20 (6.1)	12 (21.4)	49 (35.0)	---
1–3 months	151 (28.8)	82 (24.9)	13 (23.2)	56 (40.0)	---
4–6 months	112 (21.3)	81 (24.6)	13 (23.2)	18 (12.9)	---
7–12 months	181 (34.5)	146 (44.4)	18 (32.1)	17 (12.1)	---
<b>Infant sex, n (%)</b>					0.45
Female	232 (43.7)	152 (45.8)	23 (39.7)	57 (40.4)	---
Male	299 (56.3)	180 (54.2)	35 (60.3)	84 (59.6)	---
<b>Population group of infant, n (%)<sup>2</sup></b>					---
White	90 (16.9)	32 (9.6)	13 (22.4)	45 (31.9)	<0.001
South Asian	63 (11.9)	38 (11.4)	6 (10.3)	19 (13.5)	0.77
Arab/West Asian	41 (7.7)	15 (4.5)	5 (8.6)	21 (14.9)	<0.001
Black	40 (7.5)	19 (5.7)	8 (13.8)	13 (9.2)	0.06
East/Southeast Asian	25 (4.7)	18 (5.4)	<5 (<8.6)	<5 (<3.5)	0.48
Indigenous	16 (3.0)	<5 (<1.5)	6–9 (10.3–15.5)	5–8 (3.5–5.7)	<0.001
Other	14 (2.6)	9–12 (2.7–3.6)	<5 (<8.6)	<5 (<3.5)	0.57
Unknown	254 (47.8)	204 (61.4)	15 (25.9)	35 (24.8)	<0.001
<b>Region of residence, n (%)<sup>3</sup></b>					---
Québec	251 (47.3)	162 (48.8)	21 (36.2)	68 (48.2)	---
Ontario	233 (43.9)	164 (49.4)	24 (41.4)	45 (31.9)	---
West/North	47 (8.9)	6 (1.8)	13 (22.4)	28 (19.9)	---
Atlantic	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	---
<b>Gestational age at birth, n (%)<sup>4</sup></b>					<0.001
Term (≥37 weeks')	445 (88.8)	284 (93.1)	40 (70.2)	121 (87.1)	---
Late preterm (34–<37 weeks')	29 (5.8)	12 (3.9)	9 (15.8)	8 (5.8)	---
Moderate/very preterm (<34 weeks')	27 (5.4)	9 (3.0)	8 (14.0)	10 (7.2)	---
Median (IQR) weeks at birth <sup>5</sup>	34.0 (31.4–35.5)	34.0 (32.4–35.7)	34.6 (30.0–35.0)	32.9 (29.0–35.4)	0.48
<b>Any comorbid condition, n (%)</b>	59 (11.1)	23 (6.9)	18 (31.0)	18 (12.8)	<0.001
Congenital heart disease	20 (3.8)	9 (2.7)	6 (10.3)	5 (3.5)	0.03
Neurologic/neurodevelopmental	19 (3.6)	6–9 (1.8–2.7)	8–11 (13.8–19.0)	<5 (<3.5)	<0.001
Chronic lung disease	10 (1.9)	<5 (<1.5)	<5 (<8.6)	5 (3.6)	0.007
Other <sup>6</sup>	25 (4.7)	325 (97.9)	49 (84.5)	132 (93.6)	<0.001
<b>Any co-infections, n (%)<sup>7</sup></b>	47 (8.9)	17 (5.1)	18 (31.0)	12 (8.5)	---



### COVID-19 exposure, n (%)

Known close contact with confirmed SARS-CoV-2 infection	312 (58.8)	187 (56.3)	28 (48.3)	97 (68.8)	0.01
Nosocomial infection	9 (1.7)	0 (0.0)	5–8 (8.6–13.8)	<5 (<3.5)	<0.001

<sup>1</sup>Continuous age not available for 13 infants (8 outpatients, 2 non-COVID admissions, 3 COVID admissions); categorical age not available for 6 infants (3 outpatients, 2 non-COVID admissions, 1 COVID admission).

<sup>2</sup>Physicians could report multiple population groups. East/Southeast Asian includes Chinese, Filipino, Japanese, Korean, and Southeast Asian. Indigenous includes First Nations, Inuit, and Métis.

<sup>3</sup>Overall, West/North includes cases from Manitoba (n=16), Alberta (n=14), Saskatchewan (n=10), and either Northwest Territories, Nunavut, or British Columbia (n=7). Zero cases were reported from Yukon. Atlantic includes New Brunswick, Newfoundland and Labrador, Nova Scotia, and Prince Edward Island.

<sup>4</sup>Gestational age category not known for 30 infants (27 outpatients, 1 non-COVID admission, 2 COVID admissions).

<sup>5</sup>Among preterm-born infants only (i.e. <37 weeks' gestation).

<sup>6</sup>Includes 8 gastrointestinal/liver disease, 8 sickle cell/other hematologic disorder, 6 immunosuppressing conditions, 5 renal disease, and <5 not otherwise specified. Multiple conditions may have been reported.

<sup>7</sup>Includes 19 urinary tract infections, 7 invasive bacterial infections, 6 concomitant viral infections, 5 acute otitis media/bacterial pneumonia, and <5 each of candidiasis, laryngitis/pharyngitis, other benign bacterial infections, and skin and soft tissue infections.

416

417

418

419 **Table 2. Symptoms, laboratory findings, and clinical syndromes of infants with SARS-**  
 420 **CoV-2 infection**

Clinical features	All Cases	Outpatients	Inpatients	
			Not COVID-19 related	COVID-19 related
<b>Total cases reported, N</b>	531	332	58	141
<b>COVID-19 severity, n (%)</b>				
Asymptomatic	66 (12.4)	22 (6.6)	44 (75.9)	---
Outpatient care	310 (58.4)	310 (93.4)	---	---
Inpatient care, mild	125 (23.5)	---	14 (24.1)	111 (78.7)
Inpatient care, moderate	10 (1.9)	---	---	10 (7.1)
Inpatient care, severe	20 (3.8)	---	---	20 (14.2)
<b>Symptoms and signs, n (%)</b>				
Fever	353 (66.5)	232 (69.9)	14 (24.1)	107 (75.9)
Coryza	250 (47.1)	188 (56.6)	6 (10.3)	56 (39.7)
Cough	198 (37.3)	143–146 (43.1–44.0)	<5 (<8.6)	50–53 (35.5–37.6)
Decreased oral intake	133 (25.0)	77 (23.2)	6 (10.3)	50 (35.5)
Vomiting	93 (17.5)	57 (17.2)	10 (17.2)	26 (18.4)
Diarrhea	78 (14.7)	51–54 (15.4–16.3)	<5 (<8.6)	22–25 (15.6–17.7)
Respiratory distress	55 (10.4)	17–20 (5.1–6.0)	<5 (<8.6)	32–35 (22.7–24.8)
Lethargy	53 (10.0)	19 (5.7)	7 (12.1)	27 (19.1)
Rash	49 (9.2)	35–38 (10.5–11.4)	<5 (<8.6)	10–13 (7.1–9.2)
Irritability <sup>1</sup>	46 (8.7)	29–32 (8.7–9.6)	<5 (<8.6)	12–15 (8.5–10.6)
Sneezing	44 (8.3)	31 (9.3)	0 (0.0)	13 (9.2)
Tachycardia <sup>1</sup>	27 (5.1)	21 (6.3)	<5 (<8.6)	<5 (<3.5)
Conjunctivitis	13 (2.4)	6 (1.8)	0 (0.0)	7 (5.0)
<b>Laboratory findings, n (%)</b>				
Neutropenia	34 (6.4)	9–12 (2.7–3.6)	<5 (<8.6)	19–22 (13.5–15.6)
Lymphopenia	22 (4.1)	7 (2.1)	0 (0.0)	15 (10.6)
Thrombocytosis	14 (2.6)	5–8 (1.5–2.4)	<5 (<8.6)	5–8 (3.5–5.7)
Anemia	8 (1.5)	0 (0.0)	<5 (<8.6)	5–7 (3.5–5.0)
<b>Clinical syndromes, n (%)</b>				
Upper respiratory tract infection	321 (60.5)	231 (69.6)	8 (13.8)	82 (58.2)
Gastrointestinal	161 (30.3)	103 (31.0)	13 (22.4)	45 (31.9)
Bronchiolitis	20 (3.8)	6 (1.8)	0 (0.0)	14 (9.9)
Pneumonia	14 (2.6)	0 (0.0)	<5 (<8.6)	10–13 (7.1–9.2)
Coagulopathy	7 (1.3)	0 (0.0)	<5 (<8.6)	5–6 (3.5–4.3)
Seizure(s)	7 (1.3)	0 (0.0)	<5 (<8.6)	<5 (<3.5)
Hepatitis	5 (0.9)	<5 (<1.5)	0 (0.0)	<5 (<3.5)
Acute respiratory distress syndrome	<5 (<0.9)	0 (0.0)	0 (0.0)	<5 (<3.5)
Cardiac dysfunction	<5 (<0.9)	0 (0.0)	<5 (<8.6)	<5 (<3.5)
<b>Abnormal CXR, n (%) / cases with imaging</b>	32/132 (24.2)	<5/28 (<17.9)	5–8/19 (26.3–42.1)	21–24/85 (24.7–28.2)

<b>Any respiratory support required, n (%)</b>	---	---	---	23 (16.3)
Low-flow oxygen	---	---	---	15 (10.6)
High-flow nasal cannula	---	---	---	5 (3.5)
Non-invasive ventilation	---	---	---	<5 (<3.5)
Mechanical ventilation <sup>2</sup>	---	---	---	5 (3.5)
Vasopressors	---	---	---	0 (0.0)
<b>Admitted to ICU, n (%)</b>	---	---	---	14 (9.9)
<b>Infant died, n (%)</b>	<5 (<0.9)	---	---	<5 (<3.5)

<sup>1</sup>Symptoms included as write-in notes only and may therefore be underrepresented.

<sup>2</sup>Includes conventional mechanical and high-frequency oscillatory ventilation.

421 **Table 3. Logistic regression analysis of infants' characteristics associated with COVID-19 hospital admission**

Characteristics, n (% <sub>row</sub> )	Crude model		Adjusted model <sup>1</sup>		VOC adjusted model <sup>2</sup>	
	OR (95% CI)	P value	aOR (95% CI)	P value	aOR (95% CI)	P value
<b>Infant age</b>						
0–<1 month	3.59 (1.93–6.68)	<0.001	3.78 (1.97–7.26)	<0.001	3.47 (1.42–8.52)	0.007
1–3 months	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA
4–6 months	0.33 (0.18–0.60)	<0.001	0.24 (0.12–0.47)	<0.001	0.30 (0.12–0.78)	0.01
7–12 months	0.17 (0.09–0.31)	<0.001	0.13 (0.06–0.25)	<0.001	0.12 (0.05–0.34)	<0.001
<b>Infant sex</b>						
Female	1 [Reference]	NA	1 [Reference]	NA	---	---
Male	1.24 (0.83–1.86)	0.28	1.14 (0.71–1.84)	0.58	---	---
<b>Gestational age at birth</b>						
Term (≥37 weeks')	1 [Reference]	NA	1 [Reference]	NA	---	---
Late preterm (34–<37 weeks')	1.56 (0.62–3.92)	0.34	1.25 (0.42–3.72)	0.69	---	---
Moderate/very preterm (<34 weeks')	2.61 (1.03–6.58)	0.04	3.54 (1.19–10.46)	0.02	---	---
<b>Comorbid conditions</b>						
None/Unknown	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA
≥1 comorbid condition	1.97 (1.03–3.77)	0.04	4.53 (2.06–9.97)	<0.001	7.98 (2.74–23.29)	<0.001
<b>Phase of COVID-19 pandemic</b>						
1st wave (April–August 2020)	1 [Reference]	NA	1 [Reference]	NA	---	---
2nd wave (September 2020–February 2021)	1.20 (0.65–2.19)	0.56	1.37 (0.68–2.75)	0.38	---	---
3rd wave (March–May 2021)	1.16 (0.61–2.20)	0.64	1.57 (0.74–3.31)	0.24	---	---
<b>Variant of concern</b>						
Not a confirmed VOC <sup>3</sup>	1 [Reference]	NA	---	---	1 [Reference]	NA
Confirmed VOC	0.81 (0.37–1.76)	0.59	---	---	0.63 (0.27–1.48)	0.29

aOR = Adjusted odds ratio; OR = Odds ratio; VOC = variant of concern.

<sup>1</sup>Multivariable analysis was conducted among 440 complete cases, and excludes 58 non-COVID-19-related hospitalizations.

<sup>2</sup>Multivariable analysis conducted among 268 complete cases reported from the Centre Hospitalier Universitaire Sainte-Justine, Hospital for Sick Children, or Montreal Children's Hospital and occurring on or after September 1, 2020. Excludes 25 patients hospitalized for reasons other than COVID-19. Given a smaller available sample size, VOC status was forced into the multivariable model and other covariates were selected on the basis of p-values until an events-per-variable ratio of 1:10 was reached to avoid overfitting.

<sup>3</sup>Cases occurring before December 26, 2020 (i.e. first case of confirmed Alpha in Canada) were assumed as 'not a confirmed VOC'. Cases with no VOC screening and occurring on or after December 26, 2020 (n=119) were also assumed as 'not a confirmed VOC'. Excluding the latter cases from the multivariable analysis did not meaningfully change the aOR (0.62; 95% CI 0.24–1.66).

422

423

424

425

## REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 7 Apr 2020;323(13):1239–42. .
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 28 March 2020;395(10229):1054–62. .
3. Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. *Eurosurveillance*. 23 avr 2020;25(16):2000508. .
4. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA*. 28 Apr 2020;323(16):1612–4. .
5. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*. 30 Apr 2020;382(18):1708–20. .
6. Bixler D. SARS-CoV-2–Associated Deaths Among Persons Aged 21 Years — United States, February 12–July 31, 2020. *MMWR Morb Mortal Wkly Rep [Internet]*. 2020 [cited 2 feb 2021];69. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6937e4.htm>.
7. Bellino S, Punzo O, Rota MC, et al. COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy. *Pediatrics*. oct 2020;146(4). .
8. Woodruff RC, Campbell AP, Taylor CA, et al. Risk Factors for Severe COVID-19 in Children. *Pediatrics*. 2021.

9. Gale C, Quigley MA, Placzek A, et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance. *The Lancet Child & Adolescent Health*. 1 Feb 2021;5(2):113–21. .
10. Leung C. The younger the milder clinical course of COVID-19: Even in newborns? *Pediatr Allergy Immunol*. Feb 2021;32(2):358–62. .
11. Mithal LB, Machut KZ, Muller WJ, Kociolek LK. SARS-CoV-2 Infection in Infants Less than 90 Days Old. *J Pediatr*. sept 2020;224:150–2. .
12. Panetta L, Proulx C, Drouin O, et al. Clinical Characteristics and Disease Severity Among Infants With SARS-CoV-2 Infection in Montreal, Quebec, Canada. *JAMA Netw Open*. 1 Dec 2020;3(12):e2030470.
13. Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. *PLoS One*. 2021;16(1):e0246326.
14. CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek S, Gierke R, Hughes M, McNamara LA, et al. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 10 Apr 2020;69(14):422–6. .
15. van der Zalm MM, Lishman J, Verhagen LM, et al. Clinical experience with SARS CoV-2 related illness in children - hospital experience in Cape Town, South Africa. *Clin Infect Dis*. 10 nov 2020.
16. National Collaborating Centre for Infectious Diseases. Updates on COVID-19 Variants of Concern. [Cited 2021 Sept 13]; Available from: <https://nccid.ca/covid-19-variants/>.

17. Moderna. Phase 2/3 study expected to enroll 6,750 healthy pediatric participants less than 12 years of age. [Cited 2021 Sept 13]; Available from: <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-0>.
18. About the CPSP | Canadian Paediatric Surveillance Program [Internet]. [cited 28 may 2021]. Available from: <https://www.cpsp.cps.ca/about-apropos>.
19. Number of Physicians by Province/Territory and Specialty, Canada, 2019 [Internet]. Canadian Medical Association. [cited 28 may 2021]. Available from: <https://www.cma.ca/number-physicians-provinceterritory-and-specialty-canada-2019>, <https://www.cma.ca/number-physicians-provinceterritory-and-specialty-canada-2019>.
20. COVID-19 | Canadian Paediatric Surveillance Program [Internet]. [cited 28 May 2021]. Available from: <https://www.cpsp.cps.ca/surveillance/study-etude/covid-19/>.
21. Public Health Agency of Canada. Coronavirus disease (COVID-19): Outbreak update [Internet]. aem. 2020 [cited 31 May 2021]. Available from: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html?topic=tilelink>.
22. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis*. 2020;20(8):e192-e197.
23. Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. *Pediatrics*. 2021;148(2).
24. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nat Commun*. 2020;11(1):5749.



25. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. :15. .
26. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). *J Med Virol*. 2021;93(2):1057-1069.
27. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine*. 2020;24:100433.
28. Drouin O, Hepburn CM, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. *CMAJ*. 2021;193(38):E1483-E1493.
29. Smith, C., Odd, D., Harwood, R. et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. *Nat Med* (2021).  
<https://doi.org/10.1038/s41591-021-01578-1>.
30. Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: a narrative review. *World J Pediatr*. 2021;17(1):10-20.
31. Paret M, Lalani K, Hedari C, et al. SARS-CoV-2 Among Infants <90 Days of Age Admitted for Serious Bacterial Infection Evaluation. *Pediatrics*. 2021.
32. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. *Clin Microbiol Rev*. 2010;23(1):74-98.
33. Marodi L. Neonatal innate immunity to infectious agents. *Infect Immun*. 2006;74(4):1999-2006.

34. Mehaffey JH, Arnold M, Huffstetler E, Mehaffey RL, Quillian H, Mehaffey JH. Successful vertical transmission of SARS-CoV-2 antibodies after maternal vaccination. *Birth*. 2021.
35. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. *J Clin Invest*. 2021;131(19).
36. Trostle ME, Agüero-Rosenfeld ME, Roman AS, Lighter JL. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. *Am J Obstet Gynecol MF*. 2021:100481.
37. COVID Data Tracker. Vaccinations Among Pregnant People.. [Cited 2021 Nov 2]; Available from: <https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women>.
38. ICES [Internet]. ICES COVID-19 Dashboard. [cited 12 Dec 2021]. Available from: <https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard>.
39. Sagheb S, Lamsehchi A, Jafary M, Atef-Yekta R, Sadeghi K. Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. *Ital J Pediatr*. 2020;46(1):137.
40. Kumar VHS, Prasath A, Blanco C, et al. Respiratory Failure in an Extremely Premature Neonate with COVID-19. *Children (Basel)*. 2021;8(6).
41. Ng DC, Chin L, Choo PPL, Paramasivam U. COVID-19 in a premature infant. *BMJ Case Rep*. 2021;14(5).
42. Piersigilli F, Carkeek K, Hocq C, et al. COVID-19 in a 26-week preterm neonate. *Lancet Child Adolesc Health*. 2020;4(6):476-478.

43. Rivera-Hernandez P, Nair J, Islam S, Davidson L, Chang A, Elberson V. Coronavirus Disease 2019 in a Premature Infant: Vertical Transmission and Antibody Response or Lack Thereof. *AJP Rep.* 2020;10(3):e224-e227.
44. Brookman S, Cook J, Zucherman M, Broughton S, Harman K, Gupta A. Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people. *Lancet Child Adolesc Health.* 2021;5(4):e9-e10.
45. Public Health Ontario. Estimating the Prevalence and Growth of SARS-CoV-2 Variants in Ontario using Mutation Profiles. Enhanced Epidemiological Summary [Internet]. 2021 [cited 15 July 2021];69. Available from: [https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc\\_lang=en](https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en).